Diagnostic significance of microRNA-1255b-5p in prostate cancer patients and its effect on cancer cell function

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–157.
   PubMed Web of Science ®Google Scholar
• Brassell SA, Rice KR, Parker PM, et al. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol. 2011;185(1):132–137.
   PubMed Web of Science ®Google Scholar
• Welch HG, Albertsen PC. Reconsidering prostate cancer mortality - the future of PSA screening. N Engl J Med. 2020;382(16):1557–1563.
   PubMed Web of Science ®Google Scholar
• Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Koay EJ, Borowsky AD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349–358.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Eeles R. Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA. 2016;2(1):Fso87.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Smillie CL, Sirey T, Ponting CP. Complexities of post-transcriptional regulation and the modeling of ceRNA crosstalk. Crit Rev Biochem Mol Biol. 2018;53(3):231–245.
   PubMed Web of Science ®Google Scholar
• Anfossi S, Fu X, Nagvekar R, et al. MicroRNAs, regulatory messengers inside and outside cancer cells. Adv Exp Med Biol. 2018;1056:87–108.
   PubMed Web of Science ®Google Scholar
• Moya L, Meijer J, Schubert S, et al. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int J Mol Sci. 2019;20:5.
   Web of Science ®Google Scholar
• Parvaee P, Sarmadian H, Khansarinejad B, et al. Plasma level of microRNAs, miR-107, miR-194 and miR-210 as potential biomarkers for diagnosis intestinal-type gastric cancer in human. Asian Pac J Cancer Prev. 2019;20(5):1421–1426.
   PubMedGoogle Scholar
• Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204.
   PubMed Web of Science ®Google Scholar
• Rapado-González Ó, López-López R, López-Cedrún JL, et al. Cell-Free microRNAs as potential oral cancer biomarkers: From diagnosis to therapy. Cells. 2019;8:12.
   Web of Science ®Google Scholar
• Liu RSC, Olkhov-Mitsel E, Jeyapala R, et al. Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J Urol. 2018;199(6):1475–1481.
   PubMed Web of Science ®Google Scholar
• Bhagirath D, Yang TL, Bucay N, et al. microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. Cancer Res. 2018;78(7):1833–1844.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bai J, Yin H, et al. Exosomal miR-1255b-5p targets human telomerase reverse transcriptase in colorectal cancer cells to suppress epithelial-to-mesenchymal transition. Mol Oncol. 2020;14(10):2589–2608.
   PubMed Web of Science ®Google Scholar
• de Oliveira A, Castanhole-Nunes MMU, Biselli-Chicote PM, et al. Differential expression of angiogenesis-related miRNAs and VEGFA in cirrhosis and hepatocellular carcinoma. Arch Med Sci. 2020;16(5):1150–1157.
   PubMed Web of Science ®Google Scholar
• Hidaka H, Seki N, Yoshino H, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3(1):44–57.
   PubMedGoogle Scholar
• Tölle A, Jung M, Rabenhorst S, et al. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep. 2013;30(4):1949–1956.
   PubMed Web of Science ®Google Scholar
• McDonald AC, Vira M, Shen J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78(6):411–418.
   PubMed Web of Science ®Google Scholar
• Pan Z, Yang G, He H, et al. Identification of cerebrospinal fluid microRNAs associated with leptomeningeal metastasis from lung adenocarcinoma. Front Oncol. 2020;10:387.
   PubMed Web of Science ®Google Scholar
• Wei CY, Wang L, Zhu MX, et al. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4. J Exp Clin Cancer Res. 2019;38(1):137.
   PubMedGoogle Scholar
• Cheng J, Lou Y, Jiang K. Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis. Bioengineered. 2021;12(1):96–107.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. Jama. 2015;314(1):80–82.
   PubMed Web of Science ®Google Scholar
• Carter HB, Helfand B, Mamawala M, et al. Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol. 2019;75(5):743–749.
   PubMed Web of Science ®Google Scholar
• Riikonen JM, Guyatt GH, Kilpeläinen TP, et al. Decision aids for prostate cancer screening choice: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(8):1072–1082.
   PubMed Web of Science ®Google Scholar
• Liao Y, Xu K. Epigenetic regulation of prostate cancer: the theories and the clinical implications. Asian J Androl. 2019;21(3):279–290.
   PubMed Web of Science ®Google Scholar
• Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55(5):715–736.
   PubMed Web of Science ®Google Scholar
• Ji W, Sun B, Su C. Targeting microRNAs in cancer gene therapy. Genes (Basel). 2017;8:1.
   Web of Science ®Google Scholar
• Luu HN, Lin HY, Sørensen KD, et al. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;17(1):18.
   PubMed Web of Science ®Google Scholar
• Cai L, Ye L, Hu X, et al. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4. Bioengineered. 2021;12(1):440–449.
   PubMed Web of Science ®Google Scholar
• Zhang R, Guo C, Liu T, et al. MicroRNA miR-495 regulates the development of hepatocellular carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3). Bioengineered. 2021;12(1):6902–6912.
   PubMed Web of Science ®Google Scholar
• Gandellini P, Ciniselli CM, Rancati T, et al. Prediction of grade reclassification of prostate cancer patients on active surveillance through the combination of a three-miRNA signature and selected clinical variables. Cancers (Basel). 2021;13:10.
   Web of Science ®Google Scholar
• Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–379.
   PubMed Web of Science ®Google Scholar
• Schulz WA, Ingenwerth M, Djuidje CE, et al. Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer. 2010;10:505.
   PubMed Web of Science ®Google Scholar